BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Condliffe AM, Davidson K, Anderson KE, Ellson CD, Crabbe T, Okkenhaug K, Vanhaesebroeck B, Turner M, Webb L, Wymann MP. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood. 2005;106:1432-1440. [PMID: 15878979 DOI: 10.1182/blood-2005-03-0944] [Cited by in Crossref: 211] [Cited by in F6Publishing: 211] [Article Influence: 12.4] [Reference Citation Analysis]
Number Citing Articles
1 Schymeinsky J, Then C, Sindrilaru A, Gerstl R, Jakus Z, Tybulewicz VL, Scharffetter-Kochanek K, Walzog B. Syk-mediated translocation of PI3Kdelta to the leading edge controls lamellipodium formation and migration of leukocytes. PLoS One 2007;2:e1132. [PMID: 17987119 DOI: 10.1371/journal.pone.0001132] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
2 Perry B, Beevers R, Bennett G, Buckley G, Crabbe T, Gowers L, James L, Jenkins K, Lock C, Sabin V, Wright S. Optimization of a series of multi-isoform PI3 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 2008;18:5299-302. [DOI: 10.1016/j.bmcl.2008.08.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
3 Guillou H, Stephens LR, Hawkins PT. Quantitative Measurement of Phosphatidylinositol 3,4,5-trisphosphate. Lipidomics and Bioactive Lipids: Lipids and Cell Signaling. Elsevier; 2007. pp. 117-30. [DOI: 10.1016/s0076-6879(07)34007-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
4 Győri D, Csete D, Benkő S, Kulkarni S, Mandl P, Dobó-Nagy C, Vanhaesebroeck B, Stephens L, Hawkins PT, Mócsai A. The phosphoinositide 3-kinase isoform PI3Kβ regulates osteoclast-mediated bone resorption in humans and mice. Arthritis Rheumatol 2014;66:2210-21. [PMID: 24719382 DOI: 10.1002/art.38660] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
5 Sunose M, Bell K, Ellard K, Bergamini G, Neubauer G, Werner T, Ramsden N. Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease. Bioorganic & Medicinal Chemistry Letters 2012;22:4613-8. [DOI: 10.1016/j.bmcl.2012.05.090] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
6 Kearney AL, Norris DM, Ghomlaghi M, Kin Lok Wong M, Humphrey SJ, Carroll L, Yang G, Cooke KC, Yang P, Geddes TA, Shin S, Fazakerley DJ, Nguyen LK, James DE, Burchfield JG. Akt phosphorylates insulin receptor substrate to limit PI3K-mediated PIP3 synthesis. Elife 2021;10:e66942. [PMID: 34253290 DOI: 10.7554/eLife.66942] [Reference Citation Analysis]
7 Haylock-jacobs S, Comerford I, Bunting M, Kara E, Townley S, Klingler-hoffmann M, Vanhaesebroeck B, Puri KD, Mccoll SR. PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. Journal of Autoimmunity 2011;36:278-87. [DOI: 10.1016/j.jaut.2011.02.006] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 5.2] [Reference Citation Analysis]
8 Coughlan AM, Freeley SJ, Robson MG. Humanised mice have functional human neutrophils. J Immunol Methods 2012;385:96-104. [PMID: 22917930 DOI: 10.1016/j.jim.2012.08.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
9 Lazo JS, Sharlow ER, Epperly MW, Lira A, Leimgruber S, Skoda EM, Wipf P, Greenberger JS. Pharmacologic profiling of phosphoinositide 3-kinase inhibitors as mitigators of ionizing radiation-induced cell death. J Pharmacol Exp Ther 2013;347:669-80. [PMID: 24068833 DOI: 10.1124/jpet.113.208421] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
10 Zheng S, Wang S, Zhang Q, Zhang Z, Xu S. Avermectin inhibits neutrophil extracellular traps release by activating PTEN demethylation to negatively regulate the PI3K-ERK pathway and reducing respiratory burst in carp. J Hazard Mater 2020;389:121885. [PMID: 31879111 DOI: 10.1016/j.jhazmat.2019.121885] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
11 Barnes PJ. Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. Pharmacol Rev 2016;68:788-815. [PMID: 27363440 DOI: 10.1124/pr.116.012518] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]
12 Sapey E, Greenwood H, Walton G, Mann E, Love A, Aaronson N, Insall RH, Stockley RA, Lord JM. Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. Blood 2014;123:239-48. [PMID: 24191150 DOI: 10.1182/blood-2013-08-519520] [Cited by in Crossref: 182] [Cited by in F6Publishing: 166] [Article Influence: 20.2] [Reference Citation Analysis]
13 Hultqvist M, Olofsson P, Wallner FK, Holmdahl R. Pharmacological Potential of NOX2 Agonists in Inflammatory Conditions. Antioxid Redox Signal 2015;23:446-59. [PMID: 24359237 DOI: 10.1089/ars.2013.5788] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
14 Stephens L, Milne L, Hawkins P. Moving towards a better understanding of chemotaxis. Curr Biol. 2008;18:R485-R494. [PMID: 18522824 DOI: 10.1016/j.cub.2008.04.048] [Cited by in Crossref: 124] [Cited by in F6Publishing: 122] [Article Influence: 8.9] [Reference Citation Analysis]
15 Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood 2007;109:2894-902. [PMID: 17164340 DOI: 10.1182/blood-2006-07-038620] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 2.7] [Reference Citation Analysis]
16 Ghigo A, Damilano F, Braccini L, Hirsch E. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases. Bioessays. 2010;32:185-196. [PMID: 20162662 DOI: 10.1002/bies.200900150] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 6.8] [Reference Citation Analysis]
17 Kang Y, Regmi SC, Kim MY, Banskota S, Gautam J, Kim DH, Kim JA. Anti-angiogenic activity of macrolactin A and its succinyl derivative is mediated through inhibition of class I PI3K activity and its signaling. Arch Pharm Res 2015;38:249-60. [PMID: 25547980 DOI: 10.1007/s12272-014-0535-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
18 Zillikens H, Kasprick A, Osterloh C, Gross N, Radziewitz M, Hass C, Hartmann V, Behnen-Härer M, Ernst N, Boch K, Vidarsson G, Visser R, Laskay T, Yu X, Petersen F, Ludwig RJ, Bieber K. Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita. Front Med (Lausanne) 2021;8:713312. [PMID: 34557502 DOI: 10.3389/fmed.2021.713312] [Reference Citation Analysis]
19 Williams R, Berndt A, Miller S, Hon W, Zhang X. Form and flexibility in phosphoinositide 3-kinases. Biochemical Society Transactions 2009;37:615-26. [DOI: 10.1042/bst0370615] [Cited by in Crossref: 49] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
20 van Grinsven E, Leliefeld PHC, Pillay J, van Aalst CW, Vrisekoop N, Koenderman L. A comprehensive three-dimensional assay to assess neutrophil defense against bacteria. J Immunol Methods 2018;462:83-90. [PMID: 30205106 DOI: 10.1016/j.jim.2018.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
21 Cowburn AS, Condliffe AM, Farahi N, Summers C, Chilvers ER. Advances in neutrophil biology: clinical implications. Chest 2008;134:606-12. [PMID: 18779195 DOI: 10.1378/chest.08-0422] [Cited by in Crossref: 118] [Cited by in F6Publishing: 116] [Article Influence: 8.4] [Reference Citation Analysis]
22 McKay DM, Watson JL, Wang A, Caldwell J, Prescott D, Ceponis PM, Di Leo V, Lu J. Phosphatidylinositol 3'-kinase is a critical mediator of interferon-gamma-induced increases in enteric epithelial permeability. J Pharmacol Exp Ther 2007;320:1013-22. [PMID: 17178936 DOI: 10.1124/jpet.106.113639] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
23 Sapey E, Stockley RA. Red, amber and green: the role of the lung in de-priming active systemic neutrophils. Thorax 2014;69:606-8. [PMID: 24917612 DOI: 10.1136/thoraxjnl-2014-205438] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
24 Müller R, Fischer C, Wilmes T, Heimrich B, Distel V, Klugbauer N, Meyer DK. Phosphoinositide-3-kinases p110α and p110β mediate S phase entry in astroglial cells in the marginal zone of rat neocortex. Front Cell Neurosci 2013;7:24. [PMID: 23504389 DOI: 10.3389/fncel.2013.00024] [Reference Citation Analysis]
25 Pauls SD, Lafarge ST, Landego I, Zhang T, Marshall AJ. The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front Immunol. 2012;3:224. [PMID: 22908014 DOI: 10.3389/fimmu.2012.00224] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
26 Ukhanov K, Corey EA, Brunert D, Klasen K, Ache BW. Inhibitory odorant signaling in Mammalian olfactory receptor neurons. J Neurophysiol 2010;103:1114-22. [PMID: 20032232 DOI: 10.1152/jn.00980.2009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
27 Cerny O, Anderson KE, Stephens LR, Hawkins PT, Sebo P. cAMP Signaling of Adenylate Cyclase Toxin Blocks the Oxidative Burst of Neutrophils through Epac-Mediated Inhibition of Phospholipase C Activity. J Immunol 2017;198:1285-96. [PMID: 28039302 DOI: 10.4049/jimmunol.1601309] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
28 Singh AK, Pantouris G, Borosch S, Rojanasthien S, Cho TY. Structural basis for decreased induction of class IB PI3-kinases expression by MIF inhibitors. J Cell Mol Med 2017;21:142-53. [PMID: 27619729 DOI: 10.1111/jcmm.12949] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
29 Marwick JA, Caramori G, Casolari P, Mazzoni F, Kirkham PA, Adcock IM, Chung KF, Papi A. A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2010;125:1146-53. [PMID: 20381852 DOI: 10.1016/j.jaci.2010.02.003] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 6.3] [Reference Citation Analysis]
30 Hao L, Lei X, Zhou H, Marshall AJ, Liu L. Critical role for PI3Kγ-dependent neutrophil reactive oxygen species in WKYMVm-induced microvascular hyperpermeability. J Leukoc Biol 2019;106:1117-27. [PMID: 31216371 DOI: 10.1002/JLB.3A0518-184RR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Hezel AF, Ryan DP. Emerging therapies for colorectal cancer. Expert Opin Investig Drugs 2007;16:867-76. [PMID: 17501698 DOI: 10.1517/13543784.16.6.867] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Bartok B, Boyle DL, Liu Y, Ren P, Ball ST, Bugbee WD, Rommel C, Firestein GS. PI3 Kinase δ Is a Key Regulator of Synoviocyte Function in Rheumatoid Arthritis. The American Journal of Pathology 2012;180:1906-16. [DOI: 10.1016/j.ajpath.2012.01.030] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
33 Soond DR, Bjørgo E, Moltu K, Dale VQ, Patton DT, Torgersen KM, Galleway F, Twomey B, Clark J, Gaston JS, Taskén K, Bunyard P, Okkenhaug K. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 2010;115:2203-13. [PMID: 20081091 DOI: 10.1182/blood-2009-07-232330] [Cited by in Crossref: 139] [Cited by in F6Publishing: 146] [Article Influence: 11.6] [Reference Citation Analysis]
34 Sogkas G, Adriawan IR, Dubrowinskaja N, Atschekzei F, Schmidt RE. Homeostatic and pathogenic roles of PI3Kδ in the human immune system. Elsevier; 2020. pp. 109-37. [DOI: 10.1016/bs.ai.2020.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Hawkins PT, Stephens LR, Suire S, Wilson M. PI3K signaling in neutrophils. Curr Top Microbiol Immunol 2010;346:183-202. [PMID: 20473789 DOI: 10.1007/82_2010_40] [Cited by in Crossref: 26] [Cited by in F6Publishing: 47] [Article Influence: 2.4] [Reference Citation Analysis]
36 Beale G, Haagensen EJ, Thomas HD, Wang LZ, Revill CH, Payne SL, Golding BT, Hardcastle IR, Newell DR, Griffin RJ, Cano C. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer. Br J Cancer 2016;115:682-90. [PMID: 27529512 DOI: 10.1038/bjc.2016.238] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
37 Marwick JA, Chung KF, Adcock IM. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Ther Adv Respir Dis 2010;4:19-34. [PMID: 20051446 DOI: 10.1177/1753465809352792] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
38 Kasper B, Brandt E, Brandau S, Petersen F. Platelet factor 4 (CXC chemokine ligand 4) differentially regulates respiratory burst, survival, and cytokine expression of human monocytes by using distinct signaling pathways. J Immunol 2007;179:2584-91. [PMID: 17675521 DOI: 10.4049/jimmunol.179.4.2584] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
39 Kingham E, Welham M. Distinct roles for isoforms of the catalytic subunit of class-IA PI3K in the regulation of behaviour of murine embryonic stem cells. J Cell Sci 2009;122:2311-21. [PMID: 19509054 DOI: 10.1242/jcs.046557] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
40 Clark J, Anderson KE, Juvin V, Smith TS, Karpe F, Wakelam MJ, Stephens LR, Hawkins PT. Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. Nat Methods 2011;8:267-72. [PMID: 21278744 DOI: 10.1038/nmeth.1564] [Cited by in Crossref: 187] [Cited by in F6Publishing: 170] [Article Influence: 17.0] [Reference Citation Analysis]
41 Welch HC, Condliffe AM, Milne LJ, Ferguson GJ, Hill K, Webb LM, Okkenhaug K, Coadwell WJ, Andrews SR, Thelen M, Jones GE, Hawkins PT, Stephens LR. P-Rex1 regulates neutrophil function. Curr Biol. 2005;15:1867-1873. [PMID: 16243035 DOI: 10.1016/j.cub.2005.09.050] [Cited by in Crossref: 128] [Cited by in F6Publishing: 126] [Article Influence: 8.0] [Reference Citation Analysis]
42 Allen RA, Brookings DC, Powell MJ, Delgado J, Shuttleworth LK, Merriman M, Fahy IJ, Tewari R, Silva JP, Healy LJ, Davies GCG, Twomey B, Cutler RM, Kotian A, Crosby A, McCluskey G, Watt GF, Payne A. Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ. J Pharmacol Exp Ther 2017;361:429-40. [PMID: 28442583 DOI: 10.1124/jpet.116.237347] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
43 Gilio K, Munnix IC, Mangin P, Cosemans JM, Feijge MA, van der Meijden PE, Olieslagers S, Chrzanowska-Wodnicka MB, Lillian R, Schoenwaelder S, Koyasu S, Sage SO, Jackson SP, Heemskerk JW. Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation. J Biol Chem 2009;284:33750-62. [PMID: 19815551 DOI: 10.1074/jbc.M109.048439] [Cited by in Crossref: 84] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
44 Rynkiewicz NK, Anderson KE, Suire S, Collins DM, Karanasios E, Vadas O, Williams R, Oxley D, Clark J, Stephens LR, Hawkins PT. Gβγ is a direct regulator of endogenous p101/p110γ and p84/p110γ PI3Kγ complexes in mouse neutrophils. Sci Signal 2020;13:eaaz4003. [PMID: 33144519 DOI: 10.1126/scisignal.aaz4003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
45 Lv XH, Li QS, Ren ZL, Chu MJ, Sun J, Zhang X, Xing M, Zhu HL, Cao HQ. (E)-1,3-diphenyl-1H-pyrazole derivatives containing O-benzyl oxime moiety as potential immunosuppressive agents: Design, synthesis, molecular docking and biological evaluation. Eur J Med Chem 2016;108:586-93. [PMID: 26720154 DOI: 10.1016/j.ejmech.2015.12.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
46 Suire S, Lécureuil C, Anderson KE, Damoulakis G, Niewczas I, Davidson K, Guillou H, Pan D, Jonathan Clark, Phillip T Hawkins, Stephens L. GPCR activation of Ras and PI3Kc in neutrophils depends on PLCb2/b3 and the RasGEF RasGRP4. EMBO J 2012;31:3118-29. [PMID: 22728827 DOI: 10.1038/emboj.2012.167] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
47 Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K. PI3Kδ and primary immunodeficiencies. Nat Rev Immunol 2016;16:702-14. [PMID: 27616589 DOI: 10.1038/nri.2016.93] [Cited by in Crossref: 163] [Cited by in F6Publishing: 138] [Article Influence: 27.2] [Reference Citation Analysis]
48 Nguyen GT, Shaban L, Mack M, Swanson KD, Bunnell SC, Sykes DB, Mecsas J. SKAP2 is required for defense against K. pneumoniae infection and neutrophil respiratory burst. Elife 2020;9:e56656. [PMID: 32352382 DOI: 10.7554/eLife.56656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
49 Gupta V, Khan A, Higham A, Lemon J, Sriskantharajah S, Amour A, Hessel EM, Southworth T, Singh D. The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils. Int Immunopharmacol 2016;35:155-62. [PMID: 27049289 DOI: 10.1016/j.intimp.2016.03.027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
50 Lehmann K, Müller JP, Schlott B, Skroblin P, Barz D, Norgauer J, Wetzker R. PI3Kgamma controls oxidative bursts in neutrophils via interactions with PKCalpha and p47phox. Biochem J 2009;419:603-10. [PMID: 18983267 DOI: 10.1042/BJ20081268] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
51 Kim S, Garcia A, Jackson SP, Kunapuli SP. Insulin-like growth factor-1 regulates platelet activation through PI3-Kalpha isoform. Blood 2007;110:4206-13. [PMID: 17827385 DOI: 10.1182/blood-2007-03-080804] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
52 Honda F, Kano H, Kanegane H, Nonoyama S, Kim ES, Lee SK, Takagi M, Mizutani S, Morio T. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol 2012;13:369-78. [PMID: 22366891 DOI: 10.1038/ni.2234] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 8.5] [Reference Citation Analysis]
53 Wrann CD, Tabriz NA, Barkhausen T, Klos A, van Griensven M, Pape HC, Kendoff DO, Guo R, Ward PA, Krettek C, Riedemann NC. The phosphatidylinositol 3-kinase signaling pathway exerts protective effects during sepsis by controlling C5a-mediated activation of innate immune functions. J Immunol 2007;178:5940-8. [PMID: 17442978 DOI: 10.4049/jimmunol.178.9.5940] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
54 Canobbio I, Stefanini L, Cipolla L, Ciraolo E, Gruppi C, Balduini C, Hirsch E, Torti M. Genetic evidence for a predominant role of PI3Kβ catalytic activity in ITAM- and integrin-mediated signaling in platelets. Blood 2009;114:2193-6. [DOI: 10.1182/blood-2009-03-208074] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 7.9] [Reference Citation Analysis]
55 Zhang TT, Okkenhaug K, Nashed BF, Puri KD, Knight ZA, Shokat KM, Vanhaesebroeck B, Marshall AJ. Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production. J Allergy Clin Immunol. 2008;122:811-819.e2. [PMID: 19014771 DOI: 10.1016/j.jaci.2008.08.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 3.1] [Reference Citation Analysis]
56 Ward SG. T lymphocytes on the move: chemokines, PI 3-kinase and beyond. Trends in Immunology 2006;27:80-7. [DOI: 10.1016/j.it.2005.12.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
57 Gambardella L, Anderson KE, Jakus Z, Kovács M, Voigt S, Hawkins PT, Stephens L, Mócsai A, Vermeren S. Phosphoinositide 3-OH kinase regulates integrin-dependent processes in neutrophils by signaling through its effector ARAP3. J Immunol 2013;190:381-91. [PMID: 23180820 DOI: 10.4049/jimmunol.1201330] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
58 Balla T. Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev. 2013;93:1019-1137. [PMID: 23899561 DOI: 10.1152/physrev.00028.2012] [Cited by in Crossref: 875] [Cited by in F6Publishing: 790] [Article Influence: 97.2] [Reference Citation Analysis]
59 Gruen M, Rose C, König C, Gajda M, Wetzker R, Bräuer R. Loss of phosphoinositide 3-kinase gamma decreases migration and activation of phagocytes but not T cell activation in antigen-induced arthritis. BMC Musculoskelet Disord 2010;11:63. [PMID: 20374644 DOI: 10.1186/1471-2474-11-63] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
60 Jackson SP, Schoenwaelder SM. PI 3-Kinase p110β regulation of platelet integrin α(IIb)β3. Curr Top Microbiol Immunol 2010;346:203-24. [PMID: 20517720 DOI: 10.1007/82_2010_61] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
61 Aydin E, Faehling S, Saleh M, Llaó Cid L, Seiffert M, Roessner PM. Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors? Front Immunol 2020;11:595818. [PMID: 33552053 DOI: 10.3389/fimmu.2020.595818] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Randis TM, Puri KD, Zhou H, Diacovo TG. Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils. Eur J Immunol. 2008;38:1215-1224. [PMID: 18412166 DOI: 10.1002/eji.200838266] [Cited by in Crossref: 91] [Cited by in F6Publishing: 98] [Article Influence: 6.5] [Reference Citation Analysis]
63 Garcia CC, Tavares LP, Dias ACF, Kehdy F, Alvarado-Arnez LE, Queiroz-Junior CM, Galvão I, Lima BH, Matos AR, Gonçalves APF, Soriani FM, Moraes MO, Marques JT, Siqueira MM, Machado AMV, Sousa LP, Russo RC, Teixeira MM. Phosphatidyl Inositol 3 Kinase-Gamma Balances Antiviral and Inflammatory Responses During Influenza A H1N1 Infection: From Murine Model to Genetic Association in Patients. Front Immunol 2018;9:975. [PMID: 29867955 DOI: 10.3389/fimmu.2018.00975] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
64 Chang LC, Lin RH, Huang LJ, Chang CS, Kuo SC, Wang JP. Inhibition of superoxide anion generation by CHS-111 via blockade of the p21-activated kinase, protein kinase B/Akt and protein kinase C signaling pathways in rat neutrophils. Eur J Pharmacol 2009;615:207-17. [PMID: 19445920 DOI: 10.1016/j.ejphar.2009.04.050] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
65 van der Meijden PEJ, Schoenwaelder SM, Feijge MAH, Cosemans JMEM, Munnix ICA, Wetzker R, Heller R, Jackson SP, Heemskerk JWM. Dual P2Y12 receptor signaling in thrombin-stimulated platelets - involvement of phosphoinositide 3-kinase β but not γ isoform in Ca2+ mobilization and procoagulant activity: Dual P2Y12 signaling in thrombin-stimulated platelets. FEBS Journal 2008;275:371-85. [DOI: 10.1111/j.1742-4658.2007.06207.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
66 Mårdh CK, Root J, Uddin M, Stenvall K, Malmgren A, Karabelas K, Thomas M. Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease. J Immunol Res 2017;2017:5273201. [PMID: 28596972 DOI: 10.1155/2017/5273201] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
67 Cosemans JM, Munnix IC, Wetzker R, Heller R, Jackson SP, Heemskerk JW. Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 2006;108:3045-52. [PMID: 16840732 DOI: 10.1182/blood-2006-03-006338] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 6.6] [Reference Citation Analysis]
68 Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 2013;20:1364-74. [PMID: 24211136 DOI: 10.1016/j.chembiol.2013.09.017] [Cited by in Crossref: 154] [Cited by in F6Publishing: 150] [Article Influence: 17.1] [Reference Citation Analysis]
69 Westin JR. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk 2014;14:335-42. [PMID: 24650973 DOI: 10.1016/j.clml.2014.01.007] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
70 Houslay DM, Anderson KE, Chessa T, Kulkarni S, Fritsch R, Downward J, Backer JM, Stephens LR, Hawkins PT. Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells. Sci Signal 2016;9:ra82. [PMID: 27531651 DOI: 10.1126/scisignal.aae0453] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
71 Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B, Rikova K, Zhao J, Hirsch E, Benes CH, Engelman JA. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell 2015;27:97-108. [PMID: 25544637 DOI: 10.1016/j.ccell.2014.11.007] [Cited by in Crossref: 132] [Cited by in F6Publishing: 111] [Article Influence: 16.5] [Reference Citation Analysis]
72 Juvin V, Malek M, Anderson KE, Dion C, Chessa T, Lecureuil C, Ferguson GJ, Cosulich S, Hawkins PT, Stephens LR. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines. PLoS One 2013;8:e75045. [PMID: 24124465 DOI: 10.1371/journal.pone.0075045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
73 Deladeriere A, Gambardella L, Pan D, Anderson KE, Hawkins PT, Stephens LR. The regulatory subunits of PI3Kγ control distinct neutrophil responses. Sci Signal 2015;8:ra8-ra8. [DOI: 10.1126/scisignal.2005564] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
74 Hughes PJ, Lee JS, Reiner NE, Brown G. The vitamin D receptor-mediated activation of phosphatidylinositol 3-kinase (PI3Kα) plays a role in the 1α,25-dihydroxyvitamin D3-stimulated increase in steroid sulphatase activity in myeloid leukaemic cell lines. J Cell Biochem 2008;103:1551-72. [DOI: 10.1002/jcb.21545] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
75 Volk AP, Barber BM, Goss KL, Ruff JG, Heise CK, Hook JS, Moreland JG. Priming of neutrophils and differentiated PLB-985 cells by pathophysiological concentrations of TNF-α is partially oxygen dependent. J Innate Immun 2011;3:298-314. [PMID: 21088376 DOI: 10.1159/000321439] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
76 White MJ, Boyd JM, Horswill AR, Nauseef WM. Phosphatidylinositol-specific phospholipase C contributes to survival of Staphylococcus aureus USA300 in human blood and neutrophils. Infect Immun 2014;82:1559-71. [PMID: 24452683 DOI: 10.1128/IAI.01168-13] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
77 DeSouza-Vieira T, Guimarães-Costa A, Rochael NC, Lira MN, Nascimento MT, Lima-Gomez PS, Mariante RM, Persechini PM, Saraiva EM. Neutrophil extracellular traps release induced by Leishmania: role of PI3Kγ, ERK, PI3Kσ, PKC, and [Ca2+]. J Leukoc Biol 2016;100:801-10. [PMID: 27154356 DOI: 10.1189/jlb.4A0615-261RR] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
78 Banham-Hall E, Clatworthy MR, Okkenhaug K. The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases. Open Rheumatol J 2012;6:245-58. [PMID: 23028409 DOI: 10.2174/1874312901206010245] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 6.8] [Reference Citation Analysis]
79 Höland K, Boller D, Hagel C, Dolski S, Treszl A, Pardo OE, Cwiek P, Salm F, Leni Z, Shepherd PR, Styp-Rekowska B, Djonov V, von Bueren AO, Frei K, Arcaro A. Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. PLoS One 2014;9:e94132. [PMID: 24718026 DOI: 10.1371/journal.pone.0094132] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
80 Medina-Tato DA, Ward SG, Watson ML. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology 2007;121:448-61. [PMID: 17614878 DOI: 10.1111/j.1365-2567.2007.02663.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
81 Hong J, Dicker BL, Jayasinghe SN, De Gregorio F, Tian H, Han DY, Hudson KR. Strong inhibition of neutrophil–sperm interaction in cattle by selective phosphatidylinositol 3-kinase inhibitors†. Biology of Reproduction 2017;97:671-87. [DOI: 10.1093/biolre/iox121] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
82 Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K Pathway in Human Disease. Cell. 2017;170:605-635. [PMID: 28802037 DOI: 10.1016/j.cell.2017.07.029] [Cited by in Crossref: 761] [Cited by in F6Publishing: 741] [Article Influence: 152.2] [Reference Citation Analysis]
83 van Dop WA, Marengo S, te Velde AA, Ciraolo E, Franco I, ten Kate FJ, Boeckxstaens GE, Hardwick JC, Hommes DW, Hirsch E, van den Brink GR. The absence of functional PI3Kγ prevents leukocyte recruitment and ameliorates DSS-induced colitis in mice. Immunology Letters 2010;131:33-9. [DOI: 10.1016/j.imlet.2010.03.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
84 Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol 2015;23:82-91. [PMID: 26093105 DOI: 10.1016/j.coph.2015.05.017] [Cited by in Crossref: 146] [Cited by in F6Publishing: 136] [Article Influence: 20.9] [Reference Citation Analysis]
85 Heller R, Chang Q, Ehrlich G, Hsieh SN, Schoenwaelder SM, Kuhlencordt PJ, Preissner KT, Hirsch E, Wetzker R. Overlapping and distinct roles for PI3Kbeta and gamma isoforms in S1P-induced migration of human and mouse endothelial cells. Cardiovasc Res 2008;80:96-105. [PMID: 18558630 DOI: 10.1093/cvr/cvn159] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
86 Fung-Leung WP. Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function. Cell Signal 2011;23:603-8. [PMID: 20940048 DOI: 10.1016/j.cellsig.2010.10.002] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 5.8] [Reference Citation Analysis]
87 Anderson KE, Chessa TA, Davidson K, Henderson RB, Walker S, Tolmachova T, Grys K, Rausch O, Seabra MC, Tybulewicz VL, Stephens LR, Hawkins PT. PtdIns3P and Rac direct the assembly of the NADPH oxidase on a novel, pre-phagosomal compartment during FcR-mediated phagocytosis in primary mouse neutrophils. Blood 2010;116:4978-89. [PMID: 20813901 DOI: 10.1182/blood-2010-03-275602] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
88 Ellson CD, Davidson K, Ferguson GJ, O'Connor R, Stephens LR, Hawkins PT. Neutrophils from p40phox-/- mice exhibit severe defects in NADPH oxidase regulation and oxidant-dependent bacterial killing. J Exp Med 2006;203:1927-37. [PMID: 16880254 DOI: 10.1084/jem.20052069] [Cited by in Crossref: 134] [Cited by in F6Publishing: 130] [Article Influence: 8.4] [Reference Citation Analysis]
89 Suire S, Baltanas FC, Segonds-Pichon A, Davidson K, Santos E, Hawkins PT, Stephens LR. Frontline Science: TNF-α and GM-CSF1 priming augments the role of SOS1/2 in driving activation of Ras, PI3K-γ, and neutrophil proinflammatory responses. J Leukoc Biol 2019;106:815-22. [PMID: 30720883 DOI: 10.1002/JLB.2HI0918-359RR] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
90 Costa C, Martin-Conte EL, Hirsch E. Phosphoinositide 3-kinase p110γ in immunity. IUBMB Life 2011;63:707-13. [PMID: 21800408 DOI: 10.1002/iub.516] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
91 Conte E, Fruciano M, Fagone E, Gili E, Caraci F, Iemmolo M, Crimi N, Vancheri C. Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms. PLoS One. 2011;6:e24663. [PMID: 21984893 DOI: 10.1371/journal.pone.0024663] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 7.2] [Reference Citation Analysis]
92 Chu JY, Dransfield I, Rossi AG, Vermeren S. Non-canonical PI3K-Cdc42-Pak-Mek-Erk Signaling Promotes Immune-Complex-Induced Apoptosis in Human Neutrophils. Cell Rep 2016;17:374-86. [PMID: 27705787 DOI: 10.1016/j.celrep.2016.09.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
93 Taylor H, Laurence ADJ, Uhlig HH. The Role of PTEN in Innate and Adaptive Immunity. Cold Spring Harb Perspect Med 2019;9:a036996. [PMID: 31501268 DOI: 10.1101/cshperspect.a036996] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
94 Eruslanov EB, Singhal S, Albelda SM. Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap. Trends Cancer. 2017;3:149-160. [PMID: 28718445 DOI: 10.1016/j.trecan.2016.12.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 11.6] [Reference Citation Analysis]
95 Bi J, Min Z, Yuan H, Jiang Z, Mao R, Zhu T, Liu C, Zeng Y, Song J, Du C, Chen Z. PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma. Clin Transl Med 2020;9:22. [PMID: 32112175 DOI: 10.1186/s40169-020-0262-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
96 Luo HR, Mondal S. Molecular control of PtdIns(3,4,5)P3 signaling in neutrophils. EMBO Rep 2015;16:149-63. [PMID: 25576302 DOI: 10.15252/embr.201439466] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
97 Mondal S, Subramanian KK, Sakai J, Bajrami B, Luo HR. Phosphoinositide lipid phosphatase SHIP1 and PTEN coordinate to regulate cell migration and adhesion. Mol Biol Cell 2012;23:1219-30. [PMID: 22323291 DOI: 10.1091/mbc.E11-10-0889] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
98 Pascoal Ramos MI, Keşmir C, Stok JE, Geerdink R, Satravelas N, Westerlaken GHA, Meyaard L, van der Vlist M. CD200R1L is a functional evolutionary conserved activating receptor in human neutrophils. J Leukoc Biol 2021. [PMID: 33884657 DOI: 10.1002/JLB.2A0520-334R] [Reference Citation Analysis]
99 Stokes CA, Condliffe AM. Phosphoinositide 3-kinase δ (PI3Kδ) in respiratory disease. Biochem Soc Trans 2018;46:361-9. [PMID: 29523773 DOI: 10.1042/BST20170467] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
100 Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 2013;31:675-704. [PMID: 23330955 DOI: 10.1146/annurev-immunol-032712-095946] [Cited by in Crossref: 245] [Cited by in F6Publishing: 241] [Article Influence: 27.2] [Reference Citation Analysis]
101 Ghigo A, Morello F, Perino A, Hirsch E. Therapeutic applications of PI3K inhibitors in cardiovascular diseases. Future Medicinal Chemistry 2013;5:479-92. [DOI: 10.4155/fmc.13.11] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
102 Molnarfi N, Gruaz L, Dayer J, Burger D. Opposite Regulation of IL-1β and Secreted IL-1 Receptor Antagonist Production by Phosphatidylinositide-3 Kinases in Human Monocytes Activated by Lipopolysaccharides or Contact with T Cells. J Immunol 2006;178:446-54. [DOI: 10.4049/jimmunol.178.1.446] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
103 Currie KS. Targeting B-cells in Inflammatory Disease. Elsevier; 2010. pp. 175-90. [DOI: 10.1016/s0065-7743(10)45011-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Vanhaesebroeck B, Whitehead MA, Piñeiro R. Molecules in medicine mini-review: isoforms of PI3K in biology and disease. J Mol Med 2016;94:5-11. [DOI: 10.1007/s00109-015-1352-5] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 11.9] [Reference Citation Analysis]
105 Arcaro A, Doepfner KT, Boller D, Guerreiro AS, Shalaby T, Jackson SP, Schoenwaelder SM, Delattre O, Grotzer MA, Fischer B. Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochem J 2007;406:57-66. [PMID: 17506723 DOI: 10.1042/BJ20070309] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
106 Norton L, Lindsay Y, Deladeriere A, Chessa T, Guillou H, Suire S, Lucocq J, Walker S, Andrews S, Segonds-Pichon A, Rausch O, Finan P, Sasaki T, Du CJ, Bretschneider T, Ferguson GJ, Hawkins PT, Stephens L. Localizing the lipid products of PI3Kγ in neutrophils. Adv Biol Regul 2016;60:36-45. [PMID: 26596865 DOI: 10.1016/j.jbior.2015.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
107 Hasan AM, Mourtada-maarabouni M, Hameed MS, Williams GT, Dent G. Phosphoinositide 3-kinase γ mediates chemotactic responses of human eosinophils to platelet-activating factor. International Immunopharmacology 2010;10:1017-21. [DOI: 10.1016/j.intimp.2010.05.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
108 Crabbe T. Exploring the potential of PI3K inhibitors for inflammation and cancer. Biochemical Society Transactions 2007;35:253-6. [DOI: 10.1042/bst0350253] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
109 Schepetkin IA, Kirpotina LN, Khlebnikov AI, Balasubramanian N, Quinn MT. Neutrophil Immunomodulatory Activity of Natural Organosulfur Compounds. Molecules 2019;24:E1809. [PMID: 31083328 DOI: 10.3390/molecules24091809] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
110 Hawkins PT, Stephens LR. PI3K signalling in inflammation. Biochim Biophys Acta. 2015;1851:882-897. [PMID: 25514767 DOI: 10.1016/j.bbalip.2014.12.006] [Cited by in Crossref: 244] [Cited by in F6Publishing: 219] [Article Influence: 30.5] [Reference Citation Analysis]
111 Hirsch E, Ciraolo E, Ghigo A, Costa C. Taming the PI3K team to hold inflammation and cancer at bay. Pharmacol Ther. 2008;118:192-205. [PMID: 18420279 DOI: 10.1016/j.pharmthera.2008.02.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
112 Jones CN, Hoang AN, Martel JM, Dimisko L, Mikkola A, Inoue Y, Kuriyama N, Yamada M, Hamza B, Kaneki M, Warren HS, Brown DE, Irimia D. Microfluidic assay for precise measurements of mouse, rat, and human neutrophil chemotaxis in whole-blood droplets. J Leukoc Biol 2016;100:241-7. [PMID: 26819316 DOI: 10.1189/jlb.5TA0715-310RR] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
113 Riehle RD, Cornea S, Degterev A. Role of phosphatidylinositol 3,4,5-trisphosphate in cell signaling. Adv Exp Med Biol 2013;991:105-39. [PMID: 23775693 DOI: 10.1007/978-94-007-6331-9_7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
114 Nishio M, Watanabe K, Sasaki J, Taya C, Takasuga S, Iizuka R, Balla T, Yamazaki M, Watanabe H, Itoh R, Kuroda S, Horie Y, Förster I, Mak TW, Yonekawa H, Penninger JM, Kanaho Y, Suzuki A, Sasaki T. Control of cell polarity and motility by the PtdIns(3,4,5)P3 phosphatase SHIP1. Nat Cell Biol 2007;9:36-44. [PMID: 17173042 DOI: 10.1038/ncb1515] [Cited by in Crossref: 218] [Cited by in F6Publishing: 215] [Article Influence: 13.6] [Reference Citation Analysis]
115 Roller A, Perino A, Dapavo P, Soro E, Okkenhaug K, Hirsch E, Ji H. Blockade of phosphatidylinositol 3-kinase PI3Kδ or PI3Kγ reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis. J Immunol 2012;189:4612-20. [PMID: 23024273 DOI: 10.4049/jimmunol.1103173] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
116 Cheung TT, McInnes IB. Future therapeutic targets in rheumatoid arthritis? Semin Immunopathol 2017;39:487-500. [PMID: 28451787 DOI: 10.1007/s00281-017-0623-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 9.6] [Reference Citation Analysis]
117 Zeller KS, Idevall-Hagren O, Stefansson A, Velling T, Jackson SP, Downward J, Tengholm A, Johansson S. PI3-kinase p110α mediates β1 integrin-induced Akt activation and membrane protrusion during cell attachment and initial spreading. Cell Signal 2010;22:1838-48. [PMID: 20667469 DOI: 10.1016/j.cellsig.2010.07.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
118 Scott J, Ruchaud-Sparagano MH, Musgrave K, Roy AI, Wright SE, Perry JD, Conway Morris A, Rostron AJ, Simpson AJ. Phosphoinositide 3-Kinase δ Inhibition Improves Neutrophil Bacterial Killing in Critically Ill Patients at High Risk of Infection. J Immunol 2021;207:1776-84. [PMID: 34497151 DOI: 10.4049/jimmunol.2000603] [Reference Citation Analysis]
119 Huang WS, Wang TB, He Y, Chen YJ, Zhong SL, Tan M. Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948. World J Gastroenterol 2012; 18(26): 3458-3464 [PMID: 22807617 DOI: 10.3748/wjg.v18.i26.3458] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
120 Lok LSC, Farahi N, Juss JK, Loutsios C, Solanki CK, Peters AM, Donaldson F, Porter-Brown B, Chilvers ER. Effects of tocilizumab on neutrophil function and kinetics. Eur J Clin Invest 2017;47:736-45. [PMID: 28796316 DOI: 10.1111/eci.12799] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
121 Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res. 2009;82:261-271. [PMID: 19038971 DOI: 10.1093/cvr/cvn325] [Cited by in Crossref: 145] [Cited by in F6Publishing: 129] [Article Influence: 10.4] [Reference Citation Analysis]
122 Fougerat A, Smirnova NF, Gayral S, Malet N, Hirsch E, Wymann MP, Perret B, Martinez LO, Douillon M, Laffargue M. Key role of PI3Kγ in monocyte chemotactic protein-1-mediated amplification of PDGF-induced aortic smooth muscle cell migration. Br J Pharmacol 2012;166:1643-53. [PMID: 22251152 DOI: 10.1111/j.1476-5381.2012.01866.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
123 Foster JG, Blunt MD, Carter E, Ward SG. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol Rev. 2012;64:1027-1054. [PMID: 23023033 DOI: 10.1124/pr.110.004051] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 8.4] [Reference Citation Analysis]
124 Zhu J, Li K, Xu L, Jin J. Insight into the selective mechanism of phosphoinositide 3-kinase γ with benzothiazole and thiazolopiperidine γ-specific inhibitors by in silico approaches. Chem Biol Drug Des 2019;93:818-31. [PMID: 30582283 DOI: 10.1111/cbdd.13469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
125 Kim S, Mangin P, Dangelmaier C, Lillian R, Jackson SP, Daniel JL, Kunapuli SP. Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets. J Biol Chem 2009;284:33763-72. [PMID: 19700402 DOI: 10.1074/jbc.M109.048553] [Cited by in Crossref: 101] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
126 Fruman DA, Bismuth G. Fine tuning the immune response with PI3K. Immunol Rev 2009;228:253-72. [PMID: 19290933 DOI: 10.1111/j.1600-065X.2008.00750.x] [Cited by in Crossref: 157] [Cited by in F6Publishing: 91] [Article Influence: 12.1] [Reference Citation Analysis]
127 Ghigo A, Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinases in health and disease. Subcell Biochem 2012;58:183-213. [PMID: 22403077 DOI: 10.1007/978-94-007-3012-0_6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
128 Angulo I, Vadas O, Garçon F, Banham-Hall E, Plagnol V, Leahy TR, Baxendale H, Coulter T, Curtis J, Wu C, Blake-Palmer K, Perisic O, Smyth D, Maes M, Fiddler C, Juss J, Cilliers D, Markelj G, Chandra A, Farmer G, Kielkowska A, Clark J, Kracker S, Debré M, Picard C, Pellier I, Jabado N, Morris JA, Barcenas-Morales G, Fischer A, Stephens L, Hawkins P, Barrett JC, Abinun M, Clatworthy M, Durandy A, Doffinger R, Chilvers ER, Cant AJ, Kumararatne D, Okkenhaug K, Williams RL, Condliffe A, Nejentsev S. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 2013;342:866-71. [PMID: 24136356 DOI: 10.1126/science.1243292] [Cited by in Crossref: 388] [Cited by in F6Publishing: 345] [Article Influence: 43.1] [Reference Citation Analysis]
129 Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J 2008;415:97-110. [PMID: 18498248 DOI: 10.1042/BJ20080639] [Cited by in Crossref: 102] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
130 Marwick JA, Adcock IM, Chung KF. Overcoming reduced glucocorticoid sensitivity in airway disease: molecular mechanisms and therapeutic approaches. Drugs 2010;70:929-48. [PMID: 20481652 DOI: 10.2165/10898520-000000000-00000] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
131 Fougerat A, Gayral S, Malet N, Briand-Mesange F, Breton-Douillon M, Laffargue M. Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis? Clin Sci (Lond). 2009;116:791-804. [PMID: 19397491 DOI: 10.1042/cs20080549] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
132 Hu XL, Shen W, Wang R, Long H, Wang Q, Feng JH, Pham TA, Xiong F, Ye WC, Wang H. Discovery of Eucalyptin C, derived from the fruits of Eucalyptus globulus Labill., as a novel selective PI3Kγ inhibitor for immunosuppressive treatment. Chin J Nat Med 2021;19:844-55. [PMID: 34844723 DOI: 10.1016/S1875-5364(21)60111-5] [Reference Citation Analysis]
133 Roy-O'Reilly MA, Ahnstedt H, Spychala MS, Munshi Y, Aronowski J, Sansing LH, McCullough LD. Aging exacerbates neutrophil pathogenicity in ischemic stroke. Aging (Albany NY) 2020;12:436-61. [PMID: 31927534 DOI: 10.18632/aging.102632] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
134 Nie B, Cheng N, Dinauer MC, Ye RD. Characterization of P-Rex1 for its role in fMet-Leu-Phe-induced superoxide production in reconstituted COS(phox) cells. Cell Signal. 2010;22:770-782. [PMID: 20074642 DOI: 10.1016/j.cellsig.2010.01.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
135 Tiwari S, Choi HP, Matsuzawa T, Pypaert M, MacMicking JD. Targeting of the GTPase Irgm1 to the phagosomal membrane via PtdIns(3,4)P(2) and PtdIns(3,4,5)P(3) promotes immunity to mycobacteria. Nat Immunol 2009;10:907-17. [PMID: 19620982 DOI: 10.1038/ni.1759] [Cited by in Crossref: 84] [Cited by in F6Publishing: 85] [Article Influence: 6.5] [Reference Citation Analysis]
136 Ferguson GJ, Milne L, Kulkarni S, Sasaki T, Walker S, Andrews S, Crabbe T, Finan P, Jones G, Jackson S, Camps M, Rommel C, Wymann M, Hirsch E, Hawkins P, Stephens L. PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol 2007;9:86-91. [PMID: 17173040 DOI: 10.1038/ncb1517] [Cited by in Crossref: 183] [Cited by in F6Publishing: 185] [Article Influence: 11.4] [Reference Citation Analysis]
137 Boulven I, Levasseur S, Marois S, Paré G, Rollet-Labelle E, Naccache PH. Class IA phosphatidylinositide 3-kinases, rather than p110 gamma, regulate formyl-methionyl-leucyl-phenylalanine-stimulated chemotaxis and superoxide production in differentiated neutrophil-like PLB-985 cells. J Immunol 2006;176:7621-7. [PMID: 16751409 DOI: 10.4049/jimmunol.176.12.7621] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
138 Lecut C, Frederix K, Johnson DM, Deroanne C, Thiry M, Faccinetto C, Marée R, Evans RJ, Volders PG, Bours V, Oury C. P2X1 ion channels promote neutrophil chemotaxis through Rho kinase activation. J Immunol 2009;183:2801-9. [PMID: 19635923 DOI: 10.4049/jimmunol.0804007] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 5.4] [Reference Citation Analysis]
139 Kuan Y, Lin R, Lin H, Huang L, Tsai C, Tsao L, Lin C, Chang L, Wang J. Activation of phosphoinositide 3-kinase and Src family kinase is required for respiratory burst in rat neutrophils stimulated with artocarpol A. Biochemical Pharmacology 2006;71:1735-46. [DOI: 10.1016/j.bcp.2006.03.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
140 Kim HJ, Kim SR, Park JK, Kim DI, Jeong JS, Lee YC. PI3Kγ activation is required for LPS-induced reactive oxygen species generation in respiratory epithelial cells. Inflamm Res 2012;61:1265-72. [PMID: 22825625 DOI: 10.1007/s00011-012-0526-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
141 Juss JK, Hayhoe RP, Owen CE, Bruce I, Walmsley SR, Cowburn AS, Kulkarni S, Boyle KB, Stephens L, Hawkins PT, Chilvers ER, Condliffe AM. Functional redundancy of class I phosphoinositide 3-kinase (PI3K) isoforms in signaling growth factor-mediated human neutrophil survival. PLoS One 2012;7:e45933. [PMID: 23029326 DOI: 10.1371/journal.pone.0045933] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
142 Crabbe T, Welham MJ, Ward SG. The PI3K inhibitor arsenal: choose your weapon! Trends Biochem Sci 2007;32:450-6. [PMID: 17920279 DOI: 10.1016/j.tibs.2007.09.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
143 Niemietz I, Moraes AT, Sundqvist M, Brown KL. Hyaluronan primes the oxidative burst in human neutrophils. J Leukoc Biol 2020;108:705-13. [PMID: 32421905 DOI: 10.1002/JLB.3MA0220-216RR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Tzenaki N, Papakonstanti EA. p110δ PI3 kinase pathway: emerging roles in cancer. Front Oncol 2013;3:40. [PMID: 23459844 DOI: 10.3389/fonc.2013.00040] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
145 Saudemont A, Garçon F, Yadi H, Roche-Molina M, Kim N, Segonds-Pichon A, Martín-Fontecha A, Okkenhaug K, Colucci F. p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease. Proc Natl Acad Sci U S A 2009;106:5795-800. [PMID: 19297623 DOI: 10.1073/pnas.0808594106] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 3.6] [Reference Citation Analysis]
146 Gaestel M, Kotlyarov A. Small-Molecule Protein and Lipid Kinase Inhibitors in Inflammation and Specific Models for Their Evaluation. In: Kuster B, editor. Kinase Inhibitors. Totowa: Humana Press; 2012. pp. 35-44. [DOI: 10.1007/978-1-61779-337-0_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
147 Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988-1004. [PMID: 16341064 DOI: 10.1038/nrd1902] [Cited by in Crossref: 1396] [Cited by in F6Publishing: 1303] [Article Influence: 87.3] [Reference Citation Analysis]
148 Williams O, Houseman BT, Kunkel EJ, Aizenstein B, Hoffman R, Knight ZA, Shokat KM. Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs. Chem Biol 2010;17:123-34. [PMID: 20189103 DOI: 10.1016/j.chembiol.2010.01.010] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 4.8] [Reference Citation Analysis]
149 Geering B, Stoeckle C, Conus S, Simon HU. Living and dying for inflammation: neutrophils, eosinophils, basophils. Trends Immunol. 2013;34:398-409. [PMID: 23665135 DOI: 10.1016/j.it.2013.04.002] [Cited by in Crossref: 148] [Cited by in F6Publishing: 136] [Article Influence: 16.4] [Reference Citation Analysis]
150 Bergamini G, Bell K, Shimamura S, Werner T, Cansfield A, Müller K, Perrin J, Rau C, Ellard K, Hopf C, Doce C, Leggate D, Mangano R, Mathieson T, O'Mahony A, Plavec I, Rharbaoui F, Reinhard F, Savitski MM, Ramsden N, Hirsch E, Drewes G, Rausch O, Bantscheff M, Neubauer G. A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation. Nat Chem Biol 2012;8:576-82. [PMID: 22544264 DOI: 10.1038/nchembio.957] [Cited by in Crossref: 112] [Cited by in F6Publishing: 104] [Article Influence: 11.2] [Reference Citation Analysis]
151 Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan CN, Murphy PM. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 2009;61:119-61. [PMID: 19498085 DOI: 10.1124/pr.109.001578] [Cited by in Crossref: 482] [Cited by in F6Publishing: 477] [Article Influence: 37.1] [Reference Citation Analysis]
152 Smith LD, Hickman ES, Parry RV, Westwick J, Ward SG. PI3Kγ is the dominant isoform involved in migratory responses of human T lymphocytes: Effects of ex vivo maintenance and limitations of non-viral delivery of siRNA. Cellular Signalling 2007;19:2528-39. [DOI: 10.1016/j.cellsig.2007.08.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
153 Beaurepaire C, Smyth D, McKay DM. Interferon-gamma regulation of intestinal epithelial permeability. J Interferon Cytokine Res 2009;29:133-44. [PMID: 19196071 DOI: 10.1089/jir.2008.0057] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 5.8] [Reference Citation Analysis]
154 Kuroda E, Antignano F, Ho VW, Hughes MR, Ruschmann J, Lam V, Kawakami T, Kerr WG, Mcnagny KM, Sly LM, Krystal G. SHIP Represses Th2 Skewing by Inhibiting IL-4 Production from Basophils. J I 2010;186:323-32. [DOI: 10.4049/jimmunol.1002778] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
155 Gibot S, Massin F, Marcou M, Taylor V, Stidwill R, Wilson P, Singer M, Bellingan G. TREM-1 promotes survival during septic shock in mice. Eur J Immunol 2007;37:456-66. [DOI: 10.1002/eji.200636387] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 4.9] [Reference Citation Analysis]
156 Anderson KE, Boyle KB, Davidson K, Chessa TAM, Kulkarni S, Jarvis GE, Sindrilaru A, Scharffetter-kochanek K, Rausch O, Stephens LR, Hawkins PT. CD18-dependent activation of the neutrophil NADPH oxidase during phagocytosis of Escherichia coli or Staphylococcus aureus is regulated by class III but not class I or II PI3Ks. Blood 2008;112:5202-11. [DOI: 10.1182/blood-2008-04-149450] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 4.8] [Reference Citation Analysis]
157 Beer-hammer S, Zebedin E, von Holleben M, Alferink J, Reis B, Dresing P, Degrandi D, Scheu S, Hirsch E, Sexl V, Pfeffer K, Nürnberg B, Piekorz RP. The catalytic PI3K isoforms p110γ and p110δ contribute to B cell development and maintenance, transformation, and proliferation. Journal of Leukocyte Biology 2010;87:1083-95. [DOI: 10.1189/jlb.0809585] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
158 Fumagalli L, Campa CC, Germena G, Lowell CA, Hirsch E, Berton G. Class I phosphoinositide-3-kinases and SRC kinases play a nonredundant role in regulation of adhesion-independent and -dependent neutrophil reactive oxygen species generation. J Immunol 2013;190:3648-60. [PMID: 23447687 DOI: 10.4049/jimmunol.1201951] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
159 Manna P, Jain SK. Phosphatidylinositol-3,4,5-triphosphate and cellular signaling: implications for obesity and diabetes. Cell Physiol Biochem 2015;35:1253-75. [PMID: 25721445 DOI: 10.1159/000373949] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
160 Boyle KB, Gyori D, Sindrilaru A, Scharffetter-kochanek K, Taylor PR, Mócsai A, Stephens LR, Hawkins PT. Class IA Phosphoinositide 3-Kinase β and δ Regulate Neutrophil Oxidase Activation in Response to Aspergillus fumigatus Hyphae. J I 2011;186:2978-89. [DOI: 10.4049/jimmunol.1002268] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
161 Lo Y, Sauve JP, Menzies SC, Steiner TS, Sly LM. Phosphatidylinositol 3-kinase p110δ drives intestinal fibrosis in SHIP deficiency. Mucosal Immunol 2019;12:1187-200. [PMID: 31358861 DOI: 10.1038/s41385-019-0191-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Bandarage UK, Aronov AM, Cao J, Come JH, Cottrell KM, Davies RJ, Giroux S, Jacobs M, Mahajan S, Messersmith D, Moody CS, Swett R, Xu J. Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors. ACS Med Chem Lett 2021;12:129-35. [PMID: 33488974 DOI: 10.1021/acsmedchemlett.0c00573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
163 Michael M, Vermeren S. A neutrophil-centric view of chemotaxis. Essays Biochem 2019;63:607-18. [PMID: 31420450 DOI: 10.1042/EBC20190011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
164 Smith L, Webb A, Ward SG. T-lymphocyte navigation and migration: beyond the PI3K paradigm. Biochem Soc Trans 2007;35:193-8. [PMID: 17371236 DOI: 10.1042/BST0350193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
165 Juss JK, House D, Amour A, Begg M, Herre J, Storisteanu DM, Hoenderdos K, Bradley G, Lennon M, Summers C, Hessel EM, Condliffe A, Chilvers ER. Acute Respiratory Distress Syndrome Neutrophils Have a Distinct Phenotype and Are Resistant to Phosphoinositide 3-Kinase Inhibition. Am J Respir Crit Care Med 2016;194:961-73. [PMID: 27064380 DOI: 10.1164/rccm.201509-1818OC] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 13.2] [Reference Citation Analysis]
166 Schoenwaelder SM, Ono A, Sturgeon S, Chan SM, Mangin P, Maxwell MJ, Turnbull S, Mulchandani M, Anderson K, Kauffenstein G, Rewcastle GW, Kendall J, Gachet C, Salem HH, Jackson SP. Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin alpha IIb beta 3 adhesive function in platelets. J Biol Chem 2007;282:28648-58. [PMID: 17673465 DOI: 10.1074/jbc.M704358200] [Cited by in Crossref: 69] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
167 Subramanian KK, Jia Y, Zhu D, Simms BT, Jo H, Hattori H, You J, Mizgerd JP, Luo HR. Tumor suppressor PTEN is a physiologic suppressor of chemoattractant-mediated neutrophil functions. Blood 2007;109:4028-37. [PMID: 17202315 DOI: 10.1182/blood-2006-10-055319] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 5.8] [Reference Citation Analysis]
168 Ittner A, Block H, Reichel CA, Varjosalo M, Gehart H, Sumara G, Gstaiger M, Krombach F, Zarbock A, Ricci R. Regulation of PTEN activity by p38δ-PKD1 signaling in neutrophils confers inflammatory responses in the lung. J Exp Med 2012;209:2229-46. [PMID: 23129748 DOI: 10.1084/jem.20120677] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
169 Ellson C, Davidson K, Anderson K, Stephens LR, Hawkins PT. PtdIns3P binding to the PX domain of p40phox is a physiological signal in NADPH oxidase activation. EMBO J 2006;25:4468-78. [PMID: 16990793 DOI: 10.1038/sj.emboj.7601346] [Cited by in Crossref: 88] [Cited by in F6Publishing: 86] [Article Influence: 5.5] [Reference Citation Analysis]
170 Hagelauer N, Pabst AM, Ziebart T, Ulbrich H, Walter C. In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes. Clin Oral Investig 2015;19:139-48. [PMID: 24668343 DOI: 10.1007/s00784-014-1219-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
171 Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 2006;34:647-62. [PMID: 17052169 DOI: 10.1042/BST0340647] [Cited by in Crossref: 390] [Cited by in F6Publishing: 204] [Article Influence: 26.0] [Reference Citation Analysis]
172 Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125:733-747. [PMID: 16647110 DOI: 10.1016/j.cell.2006.03.035] [Cited by in Crossref: 869] [Cited by in F6Publishing: 802] [Article Influence: 54.3] [Reference Citation Analysis]
173 Amour A, Barton N, Cooper AWJ, Inglis G, Jamieson C, Luscombe CN, Morrell J, Peace S, Perez D, Rowland P, Tame C, Uddin S, Vitulli G, Wellaway N. Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease. J Med Chem 2016;59:7239-51. [DOI: 10.1021/acs.jmedchem.6b00799] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
174 Rizik DG, Klassen KJ, Dowler DA, Villegas BJ, Dixon SR. Promising though not yet proven: Emerging strategies to promote myocardial salvage. Cathet Cardiovasc Intervent 2006;68:596-606. [DOI: 10.1002/ccd.20892] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
175 Vangapandu HV, Jain N, Gandhi V. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs 2017;26:625-32. [PMID: 28388280 DOI: 10.1080/13543784.2017.1312338] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
176 Bruce I, Akhlaq M, Bloomfield GC, Budd E, Cox B, Cuenoud B, Finan P, Gedeck P, Hatto J, Hayler JF, Head D, Keller T, Kirman L, Leblanc C, Le Grand D, McCarthy C, O'Connor D, Owen C, Oza MS, Pilgrim G, Press NE, Sviridenko L, Whitehead L. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway. Bioorg Med Chem Lett 2012;22:5445-50. [PMID: 22863202 DOI: 10.1016/j.bmcl.2012.07.042] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
177 Garcia A, Kim S, Bhavaraju K, Schoenwaelder SM, Kunapuli SP. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Biochem J 2010;429:369-77. [PMID: 20441566 DOI: 10.1042/BJ20100166] [Cited by in Crossref: 70] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
178 Pittet MJ, Mempel TR. Regulation of T-cell migration and effector functions: insights from in vivo imaging studies. Immunol Rev 2008;221:107-29. [PMID: 18275478 DOI: 10.1111/j.1600-065X.2008.00584.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
179 Korkmaz B, Jenne DE, Gauthier F. Relevance of the mouse model as a therapeutic approach for neutrophil proteinase 3-associated human diseases. Int Immunopharmacol 2013;17:1198-205. [PMID: 23886601 DOI: 10.1016/j.intimp.2013.07.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
180 Uddin M, Lau LC, Seumois G, Vijayanand P, Staples KJ, Bagmane D, Cornelius V, Dorinsky P, Davies DE, Djukanović R. EGF-induced bronchial epithelial cells drive neutrophil chemotactic and anti-apoptotic activity in asthma. PLoS One 2013;8:e72502. [PMID: 24039773 DOI: 10.1371/journal.pone.0072502] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
181 Ong CW, Elkington PT, Brilha S, Ugarte-Gil C, Tome-Esteban MT, Tezera LB, Pabisiak PJ, Moores RC, Sathyamoorthy T, Patel V, Gilman RH, Porter JC, Friedland JS. Neutrophil-Derived MMP-8 Drives AMPK-Dependent Matrix Destruction in Human Pulmonary Tuberculosis. PLoS Pathog 2015;11:e1004917. [PMID: 25996154 DOI: 10.1371/journal.ppat.1004917] [Cited by in Crossref: 96] [Cited by in F6Publishing: 95] [Article Influence: 13.7] [Reference Citation Analysis]
182 Dupré-Crochet S, Erard M, Nüβe O. ROS production in phagocytes: why, when, and where? J Leukoc Biol 2013;94:657-70. [PMID: 23610146 DOI: 10.1189/jlb.1012544] [Cited by in Crossref: 216] [Cited by in F6Publishing: 205] [Article Influence: 24.0] [Reference Citation Analysis]
183 Shuttleworth S, Silva F, Tomassi C, Cecil A, Hill T, Rogers H, Townsend P. Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases. Prog Med Chem 2009;48:81-131. [PMID: 21544958 DOI: 10.1016/s0079-6468(09)04803-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
184 Shao D, Segal AW, Dekker LV. Subcellular localisation of the p40phox component of NADPH oxidase involves direct interactions between the Phox homology domain and F-actin. Int J Biochem Cell Biol 2010;42:1736-43. [PMID: 20637895 DOI: 10.1016/j.biocel.2010.07.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
185 Perry B, Alexander R, Bennett G, Buckley G, Ceska T, Crabbe T, Dale V, Gowers L, Horsley H, James L, Jenkins K, Crépy K, Kulisa C, Lightfoot H, Lock C, Mack S, Morgan T, Nicolas AL, Pitt W, Sabin V, Wright S. Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines. Bioorg Med Chem Lett 2008;18:4700-4. [PMID: 18644721 DOI: 10.1016/j.bmcl.2008.06.104] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
186 Rommel C, Camps M, Ji H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 2007;7:191-201. [PMID: 17290298 DOI: 10.1038/nri2036] [Cited by in Crossref: 305] [Cited by in F6Publishing: 294] [Article Influence: 20.3] [Reference Citation Analysis]
187 Perry MWD, Abdulai R, Mogemark M, Petersen J, Thomas MJ, Valastro B, Westin Eriksson A. Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases. J Med Chem 2019;62:4783-814. [DOI: 10.1021/acs.jmedchem.8b01298] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
188 Gambardella L, Anderson KE, Nussbaum C, Segonds-Pichon A, Margarido T, Norton L, Ludwig T, Sperandio M, Hawkins PT, Stephens L. The GTPase-activating protein ARAP3 regulates chemotaxis and adhesion-dependent processes in neutrophils. Blood. 2011;118:1087-1098. [PMID: 21490342 DOI: 10.1182/blood-2010-10-312959] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
189 Bylund J, Brown KL, Movitz C, Dahlgren C, Karlsson A. Intracellular generation of superoxide by the phagocyte NADPH oxidase: How, where, and what for? Free Radical Biology and Medicine 2010;49:1834-45. [DOI: 10.1016/j.freeradbiomed.2010.09.016] [Cited by in Crossref: 133] [Cited by in F6Publishing: 120] [Article Influence: 11.1] [Reference Citation Analysis]
190 Nuss JM, Lew Tsuhako A, Anand NK. Chapter 17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-3-Kinases. Annual Reports in Medicinal Chemistry Volume 44. Elsevier; 2009. pp. 339-56. [DOI: 10.1016/s0065-7743(09)04417-0] [Cited by in Crossref: 15] [Article Influence: 1.2] [Reference Citation Analysis]
191 Kimura H, Matsuyama Y, Araki S, Koizumi A, Kariya Y, Takasuga S, Eguchi S, Nakanishi H, Sasaki J, Sasaki T. The effect and possible clinical efficacy of in vivo inhibition of neutrophil extracellular traps by blockade of PI3K-gamma on the pathogenesis of microscopic polyangiitis. Mod Rheumatol 2018;28:530-41. [PMID: 28880680 DOI: 10.1080/14397595.2017.1367116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
192 Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008;1784:159-85. [PMID: 17997386 DOI: 10.1016/j.bbapap.2007.10.003] [Cited by in Crossref: 405] [Cited by in F6Publishing: 408] [Article Influence: 27.0] [Reference Citation Analysis]
193 Okkenhaug K. Rules of engagement: distinct functions for the four class I PI3K catalytic isoforms in immunity. Ann N Y Acad Sci 2013;1280:24-6. [PMID: 23551098 DOI: 10.1111/nyas.12027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
194 Kim N, Saudemont A, Webb L, Camps M, Ruckle T, Hirsch E, Turner M, Colucci F. The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 2007;110:3202-8. [DOI: 10.1182/blood-2007-02-075366] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 4.3] [Reference Citation Analysis]
195 Lawson CD, Donald S, Anderson KE, Patton DT, Welch HC. P-Rex1 and Vav1 cooperate in the regulation of formyl-methionyl-leucyl-phenylalanine-dependent neutrophil responses. J Immunol. 2011;186:1467-1476. [PMID: 21178006 DOI: 10.4049/jimmunol.1002738] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
196 Werner JA, Ishida K, Wisler J, Karbowski C, Kalanzi J, Bussiere J, Monticello TM. Phosphatidylinositol 3-Kinase δ Inhibitor-Induced Immunomodulation and Secondary Opportunistic Infection in the Cynomolgus Monkey ( Macaca fascicularis ). Toxicol Pathol 2020;48:949-64. [DOI: 10.1177/0192623320966238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 Rückle T, Schwarz MK, Rommel C. PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? Nat Rev Drug Discov 2006;5:903-18. [PMID: 17080027 DOI: 10.1038/nrd2145] [Cited by in Crossref: 190] [Cited by in F6Publishing: 182] [Article Influence: 11.9] [Reference Citation Analysis]
198 Campa CC, Silva RL, Margaria JP, Pirali T, Mattos MS, Kraemer LR, Reis DC, Grosa G, Copperi F, Dalmarco EM, Lima-Júnior RCP, Aprile S, Sala V, Dal Bello F, Prado DS, Alves-Filho JC, Medana C, Cassali GD, Tron GC, Teixeira MM, Ciraolo E, Russo RC, Hirsch E. Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis. Nat Commun 2018;9:5232. [PMID: 30542075 DOI: 10.1038/s41467-018-07698-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
199 Weiger MC, Parent CA. Phosphoinositides in Chemotaxis. In: Balla T, Wymann M, York JD, editors. Phosphoinositides II: The Diverse Biological Functions. Dordrecht: Springer Netherlands; 2012. pp. 217-54. [DOI: 10.1007/978-94-007-3015-1_7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
200 Suire S, Condliffe AM, Ferguson GJ, Ellson CD, Guillou H, Davidson K, Welch H, Coadwell J, Turner M, Chilvers ER, Hawkins PT, Stephens L. Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. Nat Cell Biol 2006;8:1303-9. [PMID: 17041586 DOI: 10.1038/ncb1494] [Cited by in Crossref: 126] [Cited by in F6Publishing: 123] [Article Influence: 7.9] [Reference Citation Analysis]
201 Ge Q, Moir LM, Trian T, Niimi K, Poniris M, Shepherd PR, Black JL, Oliver BG, Burgess JK. The phosphoinositide 3'-kinase p110δ modulates contractile protein production and IL-6 release in human airway smooth muscle. J Cell Physiol 2012;227:3044-52. [PMID: 22015454 DOI: 10.1002/jcp.23046] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
202 Marwick JA, Chung KF. Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010;5:297-309. [PMID: 20856829 DOI: 10.2147/copd.s7390] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
203 Ward SG, Marelli-Berg FM. Mechanisms of chemokine and antigen-dependent T-lymphocyte navigation. Biochem J 2009;418:13-27. [PMID: 19159344 DOI: 10.1042/BJ20081969] [Cited by in Crossref: 65] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
204 Vanichakarn P, Blair P, Wu C, Freedman JE, Chakrabarti S. Neutrophil CD40 enhances platelet-mediated inflammation. Thrombosis Research 2008;122:346-58. [DOI: 10.1016/j.thromres.2007.12.019] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
205 McCormick B, Chu JY, Vermeren S. Cross-talk between Rho GTPases and PI3K in the neutrophil. Small GTPases 2019;10:187-95. [PMID: 28328290 DOI: 10.1080/21541248.2017.1304855] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
206 Maus UA, Backi M, Winter C, Srivastava M, Schwarz MK, Rückle T, Paton JC, Briles D, Mack M, Welte T, Maus R, Bohle RM, Seeger W, Rommel C, Hirsch E, Lohmeyer J, Preissner KT. Importance of Phosphoinositide 3-Kinase γ in the Host Defense against Pneumococcal Infection. Am J Respir Crit Care Med 2007;175:958-66. [DOI: 10.1164/rccm.200610-1533oc] [Cited by in Crossref: 53] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
207 Vogt KL, Summers C, Chilvers ER, Condliffe AM. Priming and de-priming of neutrophil responses in vitro and in vivo. Eur J Clin Invest 2018;48 Suppl 2:e12967. [PMID: 29896919 DOI: 10.1111/eci.12967] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
208 Rommel C. Taking PI3Kδ and PI3Kγ One Step Ahead: Dual Active PI3Kδ/γ Inhibitors for the Treatment of Immune-Mediated Inflammatory Diseases. In: Rommel C, Vanhaesebroeck B, Vogt PK, editors. Phosphoinositide 3-kinase in Health and Disease. Berlin: Springer Berlin Heidelberg; 2011. pp. 279-99. [DOI: 10.1007/82_2010_79] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
209 Marwick JA, Caramori G, Stevenson CS, Casolari P, Jazrawi E, Barnes PJ, Ito K, Adcock IM, Kirkham PA, Papi A. Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 2009;179:542-8. [PMID: 19164702 DOI: 10.1164/rccm.200810-1570OC] [Cited by in Crossref: 166] [Cited by in F6Publishing: 64] [Article Influence: 12.8] [Reference Citation Analysis]
210 Lee CM, Gupta S, Parodo J, Wu J, Marshall JC, Hu J. The uncovering of ESE-1 in human neutrophils: implication of its role in neutrophil function and survival. Genes Immun 2015;16:356-61. [PMID: 25906252 DOI: 10.1038/gene.2015.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
211 Cai Y, Yu J, Ren P, He J, Wu Z, Xiao K, Jia H, Wang J, Sai Y, Dai G, Li X, Su W, Ngo K, Castro G, Acton PD, Fung-Leung WP, Edwards JP, Venable J, Rao TS. Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor. Pharmacol Res Perspect 2020;8:e00559. [PMID: 31956418 DOI: 10.1002/prp2.559] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
212 Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Sci Transl Med 2017;9:eaal4682. [PMID: 28539475 DOI: 10.1126/scitranslmed.aal4682] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 12.8] [Reference Citation Analysis]
213 Khwaja A. PI3K as a target for therapy in haematological malignancies. Curr Top Microbiol Immunol 2010;347:169-88. [PMID: 20517718 DOI: 10.1007/82_2010_71] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]